These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 8009254)

  • 1. Intravenous pamidronate: evolution of an effective treatment strategy.
    Anderson DC; Richardson PC; Brown JK; Freemont AJ; Hollis S; Denton J; Buckler HM; Hargreaves S; Cantrill JA
    Semin Arthritis Rheum; 1994 Feb; 23(4):273-5. PubMed ID: 8009254
    [No Abstract]   [Full Text] [Related]  

  • 2. Intravenous pamidronate in Paget's disease--response is dependent on radiographic and biochemical severity.
    Stuckey BG; Gutteridge DH; Stewart GO; Prince RL; Ward LC; Kent GN; Prince RI; Retallack RW; Bhagat CI; Nicholson GC
    Semin Arthritis Rheum; 1994 Feb; 23(4):286. PubMed ID: 8009263
    [No Abstract]   [Full Text] [Related]  

  • 3. Long-term efficacy of intravenous pamidronate in Paget's disease of bone.
    Grauer A; Klar B; Scharla SH; Zieglar R
    Semin Arthritis Rheum; 1994 Feb; 23(4):283-4. PubMed ID: 8009261
    [No Abstract]   [Full Text] [Related]  

  • 4. Intravenous aminopropylidene bisphosphonate in the treatment of severe polyostotic Paget's disease of bone.
    Fritz P; Lioté F; Kuntz D
    Semin Arthritis Rheum; 1994 Feb; 23(4):282. PubMed ID: 8009260
    [No Abstract]   [Full Text] [Related]  

  • 5. Response of biochemical markers of bone turnover to pamidronate infusion in Paget's disease of bone.
    Sharp CA; Worsfold M; Rowlands PR; Davie MW
    Semin Arthritis Rheum; 1994 Feb; 23(4):242-3. PubMed ID: 8009239
    [No Abstract]   [Full Text] [Related]  

  • 6. Clinical experience with pamidronate in the treatment of Paget's disease of bone.
    Gallacher SJ; Boyce BF; Patel U; Jenkins A; Ralston SH; Boyle IT
    Ann Rheum Dis; 1991 Dec; 50(12):930-3. PubMed ID: 1768163
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment of Paget's disease with intermittent low-dose infusions of disodium pamidronate (APD).
    Stone MD; Hawthorne AB; Kerr D; Webster G; Hosking DJ
    J Bone Miner Res; 1990 Dec; 5(12):1231-5. PubMed ID: 2075835
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bone scintigraphy following intravenous pamidronate for Paget's disease of bone.
    Ryan PJ; Gibson T; Fogelman I
    J Nucl Med; 1992 Sep; 33(9):1589-93. PubMed ID: 1517830
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Use of the bisphosphonate space in treatment and retreatment of Paget's disease.
    Stone MD; Patel S; Hosking DJ
    Semin Arthritis Rheum; 1994 Feb; 23(4):278. PubMed ID: 8009256
    [No Abstract]   [Full Text] [Related]  

  • 10. Clinical, biochemical, hematologic, and radiographic responses in Paget's disease following intravenous pamidronate disodium: a 2-year study.
    Gutteridge DH; Retallack RW; Ward LC; Stuckey BG; Stewart GO; Prince RL; Kent GN; Bhagat CI; Price RI; Thompson RI; Nicholson GC
    Bone; 1996 Oct; 19(4):387-94. PubMed ID: 8894145
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A single infusion of the bisphosphonate AHPrBP (APD) as treatment of Paget's disease of bone.
    Thiébaud D; Jaeger P; Gobelet C; Jacquet AF; Burckhardt P
    Am J Med; 1988 Aug; 85(2):207-12. PubMed ID: 3261129
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Paget's disease and its therapeutic management].
    Orcel P; Rousière M
    Presse Med; 2005 Apr; 34(8):612-6. PubMed ID: 15962504
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Therapy of Paget's disease with bisphosphonate pamidronate (AHPrBP, formerly APD)].
    Scharla SH; Grauer A; Ziegler R
    Klin Wochenschr; 1991 Jan; 69(1):25-30. PubMed ID: 2016845
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Paget's disease of bone: early and late responses to three different modes of treatment with aminohydroxypropylidene bisphosphonate (APD).
    Harinck HI; Papapoulos SE; Blanksma HJ; Moolenaar AJ; Vermeij P; Bijvoet OL
    Br Med J (Clin Res Ed); 1987 Nov; 295(6609):1301-5. PubMed ID: 3120987
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Single-day intravenous pamidronate in Paget's disease.
    Hooper MJ; Clifton-Bligh P; Marel GM; Lang FV; Tancred J; McDowall D; Forman L
    Semin Arthritis Rheum; 1994 Feb; 23(4):276-7. PubMed ID: 8009255
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical and biological effects of low doses of (3 amino-1 hydroxypropylidene)-1,1-bisphosphonate (APD) in Paget's disease of bone.
    Heynen G; Delwaide P; Bijvoet OL; Franchimont P
    Eur J Clin Invest; 1982 Feb; 12(1):29-35. PubMed ID: 6802650
    [No Abstract]   [Full Text] [Related]  

  • 17. Effects of intravenous pamidronate therapy on Paget's disease of bone.
    Bombassei GJ; Yocono M; Raisz LG
    Am J Med Sci; 1994 Oct; 308(4):226-33. PubMed ID: 7942981
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pamidronate sodium and calcitonin-resistant Paget's disease. Immediate response in a patient.
    Drake S; Massie JD; Postlethwaite AE; Palmieri GM
    Arch Intern Med; 1989 Feb; 149(2):401-3. PubMed ID: 2783843
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Strategies of treatment of Paget's disease with bisphosphonates.
    Papapoulos SE
    Semin Arthritis Rheum; 1994 Feb; 23(4):265-6. PubMed ID: 8009248
    [No Abstract]   [Full Text] [Related]  

  • 20. Treatment of Paget's disease of bone with intravenous pamidronate: comparison of 2 different modes of treatment.
    Ismail AA; Fox P; Stamp TC; Dhillon V; Crisp AJ; MacGregor A
    J Rheumatol; 1997 Nov; 24(11):2266-7. PubMed ID: 9375899
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.